Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) insider Jonathan Slonin sold 3,040 shares of the company's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $23.23, for a total transaction of $70,619.20. Following the transaction, the insider directly owned 216,384 shares of the company's stock, valued at approximately $5,026,600.32. This represents a 1.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Pacira BioSciences Trading Up 3.3%
Shares of PCRX stock opened at $24.00 on Wednesday. The firm's 50-day simple moving average is $24.82 and its 200-day simple moving average is $23.60. The company has a debt-to-equity ratio of 0.54, a current ratio of 5.04 and a quick ratio of 3.94. Pacira BioSciences, Inc. has a 1-year low of $18.80 and a 1-year high of $27.66. The firm has a market cap of $956.64 million, a P/E ratio of 68.57 and a beta of 0.27.
Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $0.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.65 by $0.08. Pacira BioSciences had a net margin of 1.96% and a return on equity of 9.68%. The firm had revenue of $192.40 million during the quarter, compared to the consensus estimate of $191.06 million. During the same period in the previous year, the firm earned $0.74 earnings per share. Pacira BioSciences's revenue was up 6.2% compared to the same quarter last year. As a group, equities analysts forecast that Pacira BioSciences, Inc. will post 1.98 EPS for the current year.
Hedge Funds Weigh In On Pacira BioSciences
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. boosted its position in Pacira BioSciences by 5,900.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,500 shares of the company's stock worth $39,000 after purchasing an additional 1,475 shares during the period. Meeder Asset Management Inc. purchased a new position in Pacira BioSciences in the first quarter valued at about $46,000. Kestra Advisory Services LLC acquired a new position in shares of Pacira BioSciences during the fourth quarter worth about $48,000. Eurizon Capital SGR S.p.A. acquired a new position in shares of Pacira BioSciences during the fourth quarter worth about $51,000. Finally, Global Retirement Partners LLC acquired a new position in shares of Pacira BioSciences during the second quarter worth about $51,000. Institutional investors and hedge funds own 99.73% of the company's stock.
Wall Street Analysts Forecast Growth
A number of analysts have recently commented on PCRX shares. Royal Bank Of Canada upped their price objective on Pacira BioSciences from $24.00 to $25.00 and gave the stock a "sector perform" rating in a report on Wednesday, August 5th. Wall Street Zen downgraded Pacira BioSciences from a "strong-buy" rating to a "buy" rating in a research report on Sunday. Weiss Ratings restated a "sell (d+)" rating on shares of Pacira BioSciences in a research note on Monday. Needham & Company LLC raised their price objective on Pacira BioSciences from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $38.00 price objective on shares of Pacira BioSciences in a research note on Wednesday, July 1st. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $30.20.
Check Out Our Latest Stock Analysis on PCRX
Pacira BioSciences Company Profile
(
Get Free Report)
Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company's flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.
In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
